Hologic (HOLX) Scheduled to Post Quarterly Earnings on Thursday

Hologic (NASDAQ:HOLX) is scheduled to be announcing its earnings results after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.98 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. During the same quarter last year, the company earned $1.07 earnings per share. The company’s revenue for the quarter was down 5.7% on a year-over-year basis. On average, analysts expect Hologic to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Hologic Stock Down 0.6 %

HOLX stock opened at $76.71 on Thursday. Hologic has a twelve month low of $64.02 and a twelve month high of $87.88. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. The stock’s 50 day moving average is $75.95 and its 200-day moving average is $72.72. The firm has a market capitalization of $18.01 billion, a PE ratio of 36.36, a P/E/G ratio of 2.58 and a beta of 1.00.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on HOLX shares. Raymond James raised their target price on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Wednesday, April 10th. Evercore ISI lifted their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. StockNews.com lowered Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Finally, William Blair reiterated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Six research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $87.00.

Insiders Place Their Bets

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now directly owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now directly owns 1,572 shares of the company’s stock, valued at $119,802.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now directly owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The disclosure for this sale can be found here. Insiders sold 32,846 shares of company stock valued at $2,473,443 over the last ninety days. 1.75% of the stock is currently owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.